TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06563895: Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Sponsor: Eidos Therapeutics, a BridgeBio company · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 587 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT06563895 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06563895 Rescue Dossier →